FUTURE OF HEALTHCARE

Exo® Acquires Medo AI to Make Medical Imaging as Easy as Snapping a Smartphone Photo

Exo | July 27, 2022 | Read time : 42:11 min

Exo® Acquires

Exo a pioneering health information and medical devices company, announced that it is acquiring Medo, a Canadian developer of artificial intelligence (AI) technology, to make ultrasound imaging faster and simpler to use. By integrating Medo’s proprietary Sweep AI™ technology into its ultrasound platform, Exo will make ultrasound imaging more accessible to a wider range of caregivers.

Ultrasound imaging is complex and requires specialized education and training. This limits the number of caregivers who can use point-of-care ultrasound to significantly improve patient care. Medo’s unique ultrasound AI technology radically lowers the expertise required to diagnose common and critical conditions through automated image acquisition and interpretation, allowing non-experts to conduct high-quality exams quickly and accurately.

Medo’s two FDA-cleared AI algorithms, with more in development, combined with access to an extensive library of millions of ultrasound images and longitudinal health data bring a unique opportunity to speed point-of-care ultrasound adoption across the healthcare system — dramatically expanding early disease detection and accelerating the path to treatment. Medo also has strong partnerships with health systems worldwide, including top healthcare institutions in Asia and Canada, enabling global clinical validation and adoption.

“This acquisition is about bringing unprecedented ease of use to ultrasound imaging — allowing caregivers to easily obtain and interpret ultrasound images,” said Sandeep Akkaraju, CEO and Founder of Exo. “Medo has built a robust AI pipeline to go from acquiring medical images to FDA-cleared software. We are excited about joining forces with an innovative team that shares our vision of taking medical imaging everywhere.”

"Exo’s powerful hardware and workflow technologies and Medo’s AI will dramatically reduce the challenges that have long held back the widespread adoption of point-of-care ultrasound. The ease of imaging and immediacy of diagnostic information we provide will radically transform medical care, creating a world where caregivers can image the body as easily as snapping a photo on a smartphone.”

Dornoosh Zonoobi, CEO of Medo

Exo recently launched Exo Works™, an intuitive point-of-care ultrasound workflow solution that streamlines documentation, billing, and quality assurance all from one platform, and will be commercializing a handheld ultrasound device that uses radically new technology to deliver powerful imaging at a fraction of the cost of a cart-based system.

About Exo
Exo is a health information and devices company. Exo believes everyone around the world should have access to high-quality, affordable and easy-to-use medical imaging. The company is on a mission to modernize medical imaging through its high-performance ultrasound platform and artificial intelligence. Exo’s goal is to enable healthcare professionals to make critical, real-time decisions that ultimately improve patient outcomes. 

This press release contains forward-looking statements regarding Exo’s future expectations, plans and prospects and are based on Exo’s current expectations and speak only as of the date hereof. Exo disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

Spotlight

ake a 5 ½ minute tour of what it is like to be a Quest Diagnostics Patient Services Representative. In this Realistic Job Preview video learn about key aspects of the role and desired candidate attributes before you apply. We don’t refer to ourselves as phlebotomists, but Patient Services Representatives. Our jobs are so much more than just drawing blood. We’re always looking for talented people who want to grow and advance with us. So if you are passionate about healthcare, and you sincerely do want to help others we invite you to apply for a Patient Services Representative role that matches your skills.

Spotlight

ake a 5 ½ minute tour of what it is like to be a Quest Diagnostics Patient Services Representative. In this Realistic Job Preview video learn about key aspects of the role and desired candidate attributes before you apply. We don’t refer to ourselves as phlebotomists, but Patient Services Representatives. Our jobs are so much more than just drawing blood. We’re always looking for talented people who want to grow and advance with us. So if you are passionate about healthcare, and you sincerely do want to help others we invite you to apply for a Patient Services Representative role that matches your skills.

Related News

HEALTH TECHNOLOGY

Netsmart Announces Intent to Become a Qualified Health Information Network to Drive the Evolution of Interoperability

Netsmart | September 23, 2022

Netsmart, the developer of the industry-leading CareFabric® platform for human services, post-acute care providers and payers announced its intent to apply to join the Trusted Exchange Framework and Common Agreement to become a Qualified Health Information Network. By supporting TEFCA, Netsmart continues its decade-long advancement of interoperability strategies to facilitate an open exchange of longitudinal healthcare data that will benefit individuals receiving care across the healthcare ecosystem. Once accepted as a QHIN, Netsmart will be part of a first-of-a-kind national data sharing network that will determine new standards for both private and public sectors. The Office of the National Coordinator for Health Information Technology is leading the charge and will oversee the QHIN process through the designation of The Sequoia Project as the recognized coordinating entity. Netsmart has been collaborating with the ONC and The Sequoia Project to help develop and provide feedback on the principles and procedures put forth by TEFCA. Netsmart is a longtime leader and advocate for open networks and interoperability standards to prioritize the needs of providers, clinicians, patients, and their families. This open network approach is in contrast to technology vendors who in some cases have sought to carve out proprietary networks that stifle the future of care coordination. The open and secure sharing of data is required to achieve effective care coordination that Netsmart supports as a founding member of the Carequality interoperability framework. The Netsmart network, CareConnect™, was built to offer clients seamless integration of health data and one point of access to the larger health data ecosystem. With the CareConnect solution, Netsmart was one of the first healthcare IT vendors to utilize the new 360X closed-loop referral standards in a production environment to bring to life true interoperability to minimize manual data entry which streamlines transitions of care and care coordination and reduces medication errors. By empowering providers to digitize their enterprise, Netsmart clients are projected to perform more than 3 billion secure health data exchanges facilitated through CareConnect in 2022. “It has always been our objective as a healthcare technology partner to offer comprehensive solutions and services that allow providers to remain competitive in a landscape that requires coordinated care and value-based practices for success. Becoming a Qualified Health Information Network aligns with our established history of being at the forefront of driving interoperability. As we take the next step in the evolution of data exchange, we look forward to collaborating with other healthcare IT vendors applying to participate as a QHIN to expand access to open networks for consumers nationwide.” Netsmart CEO Mike Valentine About Netsmart Netsmart, a leading provider of Software as a Service technology and services solutions, designs, builds and delivers electronic health records, health information exchanges, analytics and telehealth solutions and services that are powerful, intuitive and easy-to-use. Our platform provides accurate, up-to-date information that is easily accessible to care team members in the human services and post-acute care (which is comprised of home care and hospice and senior living) and payer markets. We make the complex simple and personalized so our clients can concentrate on what they do best: provide services and treatment that support whole-person care. By leveraging the powerful Netsmart network, care providers can seamlessly and securely integrate information across communities, collaborate on the most effective treatments and improve outcomes for those in their care. Our streamlined systems and personalized workflows put relevant information at the fingertips of users when and where they need it.

Read More

HEALTH TECHNOLOGY

MedAllies Selects Lyniate for Enhanced Identity Data Management Capabilities

Lyniate and MedAllies | August 22, 2022

Lyniate, a global leader in healthcare data interoperability, announced MedAllies, a leading multimodality connectivity services company, has chosen Lyniate Enterprise Master Patient Index (EMPI) by NextGate to better serve its healthcare clients and partners. This integration will bolster MedAllies’ identity data management capabilities to increase the accuracy of the data it exchanges for the benefit of all. As the healthcare industry continues to shift toward a more consumer-centric approach to interoperability, MedAllies maintains its commitment to providing connectivity services to thousands of healthcare providers and organizations across the country. The company turned to Lyniate for its proven identity management solutions and unparalleled approach to facilitating real-time data exchange. “MedAllies realized the pressing need to invest in EMPI technology, and we are excited to partner and provide solutions that will strengthen the company’s data exchange services. MedAllies understands the need to ensure the data it helps customers exchange is accurate so as not to negatively impact care, and recognizes that more accurate data can better support MedAllies’ own strategic initiatives. We applaud MedAllies for prioritizing this investment and having the vision to bring this crucial capability to its customers.” Scott Galbari, president and COO of Lyniate Lyniate EMPI has the flexibility to support on-premises and cloud deployments with the ability to adapt and scale over time. It offers options for resolution of data issues using referential data as well as manual data remediation. Beyond its proven technology, Lyniate offers a world-class, hands-on approach to customer support and training to ensure its clients maximize their investment in patient data accuracy. “Our clients and partners have spoken clearly: They need identity data solutions to be confident in the accuracy of the data that powers their businesses,” said Tom Visotsky, chief commercial officer at MedAllies. “After a great deal of due diligence, we came to the conclusion that Lyniate offers the most mature and robust EMPI solution on the market. We are excited to bring this powerful capability to meet our clients’ needs, fortify our care quality offering, and help our partners to thrive in a data-driven and consumer-focused healthcare environment.” About Lyniate Lyniate partners with healthcare organizations around the globe delivering a flexible interoperability suite that reliably connects people and the quality data they need. As a trusted partner, Lyniate powers the applications and workflows that improve clinical, operational, and financial outcomes today while helping healthcare teams to understand, prepare for, and influence changes on the horizon. Lyniate is committed to empowering people with Best-in-KLAS® ranking interoperability solutions for healthcare, from specialty clinics to large care networks, from health insurance providers to health technology, and everything in between. About MedAllies MedAllies securely delivers vital health information to impact care by operating multiple national networks supporting interoperability for all healthcare constituents. We are focused on network and service excellence for individuals, connections, and participants accessing our Connectivity Services. We serve more than 700 hospitals, 5,000 organizations, 100,000 providers, and dozens of partners bringing together millions for a more fluid healthcare experience.

Read More

HEALTH TECHNOLOGY

Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio

Axonics, Inc. | August 18, 2022

Axonics, Inc. a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that in the last twelve months, the United States Patent and Trademark Office has granted eight patents and allowed four patent applications related to the company’s sacral neuromodulation technology. The patents and allowed applications are part of Axonics’ patent portfolio and represents technology internally developed by the company covering a range of subject matter that includes the Axonics external trial system, tined lead, implantable neurostimulator, clinician programmer, wireless charging system and patient remote control. “Axonics is committed to developing best-in-class technology to serve the unmet needs of the millions of adults suffering from incontinence. The volume, subject matter diversity, and breadth of these patents demonstrate the investment in innovation that Axonics continues to make in sacral neuromodulation technology,” Raymond W. Cohen, chief executive officer About Axonics Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas. Axonics sacral neuromodulation (SNM) systems provide adults suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.

Read More